Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 12 75 59 29 6 44 15 72

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:987
ICD9CM 35 704.0 704.00
MeSH 44 D000505
NCIt 50 C50575
SNOMED-CT 68 56317004
ICD10 33 L65.9
UMLS via Orphanet 73 C0002170
Orphanet 59 ORPHA79364
UMLS 72 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and androgenic alopecia, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is SASH1 (SAM And SH3 Domain Containing 1), and among its related pathways/superpathways are Adhesion and Cell adhesion_Endothelial cell contacts by junctional mechanisms. The drugs Acitretin and fluindione have been mentioned in the context of this disorder. Affiliated tissues include Hair and Hair, and related phenotypes are no effect and Mildly decreased CFP-tsO45G cell surface transport

Wikipedia : 75 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1036)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 34.5 MBTPS2 HR FOXN1 AIRE
2 androgenic alopecia 34.4 HR AR
3 hypotrichosis 32.6 HR GJA1 DCAF17
4 clouston syndrome 32.5 TP63 GJA1 ANTXR1
5 atrichia with papular lesions 32.3 VDR HR
6 nail disorder, nonsyndromic congenital, 1 32.1 TP63 MBTPS2 AIRE
7 keratosis 31.1 MBTPS2 GJA1 DSP
8 hair disease 29.9 VDR MBTPS2 FOXN1 DSP DCAF17 ANTXR1
9 cardiomyopathy, dilated, with woolly hair and keratoderma 29.8 GJA1 DSP
10 alopecia areata 12.9
11 alopecia, androgenetic, 1 12.7
12 palmoplantar keratoderma and congenital alopecia 2 12.7
13 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 12.7
14 palmoplantar keratoderma and congenital alopecia 1 12.6
15 alopecia totalis 12.6
16 frontal fibrosing alopecia 12.6
17 mandibulofacial dysostosis with alopecia 12.6
18 alopecia, neurologic defects, and endocrinopathy syndrome 12.6
19 central centrifugal cicatricial alopecia 12.5
20 alopecia, congenital 12.5
21 alopecia-mental retardation syndrome 1 12.5
22 polyposis, skin pigmentation, alopecia, and fingernail changes 12.5
23 diffuse alopecia areata 12.5
24 alopecia, epilepsy, pyorrhea, mental subnormality 12.5
25 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.4
26 alopecia-intellectual disability syndrome 12.4
27 alopecia-contractures-dwarfism-intellectual disability syndrome 12.4
28 alopecia-contractures-dwarfism mental retardation syndrome 12.4
29 alopecia areata 1 12.4
30 cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma 12.4
31 alopecia-epilepsy-oligophrenia syndrome of moynahan 12.3
32 odonto onycho dysplasia with alopecia 12.3
33 ichthyosis alopecia eclabion ectropion mental retardation 12.2
34 hypergonadotropic hypogonadism and partial alopecia 12.2
35 alopecia areata 2 12.2
36 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 12.2
37 alopecia, androgenetic, 2 12.2
38 alopecia-mental retardation syndrome 2 12.2
39 alopecia intellectual disability syndrome 2 12.2
40 alopecia-mental retardation syndrome 3 12.2
41 alopecia universalis onychodystrophy vitiligo 12.2
42 woodhouse-sakati syndrome 12.2
43 alopecia-mental retardation syndrome with convulsions and hypergonadotropic hypogonadism 12.2
44 alopecia, familial focal 12.2
45 ichthyosis with alopecia, eclabium, ectropion, and mental retardation 12.2
46 lichen planopilaris 12.1
47 genetic alopecia 12.1
48 alopecia universalis congenita, xy gonadal dysgenesis, and laryngomalacia 12.1
49 frontonasal dysplasia with alopecia and genital anomaly 12.1
50 gapo syndrome 12.1

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
2 Mildly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.73 AHSG AIRE ANTXR1 AR DCAF17 DSP

MGI Mouse Phenotypes related to Alopecia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 ANTXR1 AR AUTS2 DCAF17 DSP EDNRA
2 growth/size/body region MP:0005378 10.32 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
3 cardiovascular system MP:0005385 10.26 ANTXR1 AR AUTS2 DSP EDNRA FOXN1
4 endocrine/exocrine gland MP:0005379 10.24 AIRE ANTXR1 AR AUTS2 EDNRA FOXN1
5 craniofacial MP:0005382 10.19 ANTXR1 AR DSP EDNRA GJA1 HR
6 mortality/aging MP:0010768 10.18 AIRE ANTXR1 AR AUTS2 CLDN1 DSP
7 integument MP:0010771 10.14 AR CLDN1 DSP EDNRA FOXN1 GJA1
8 digestive/alimentary MP:0005381 10.13 AIRE AR DSP EDNRA HR KRT14
9 immune system MP:0005387 10.13 AIRE ANTXR1 AR EDNRA FOXN1 GJA1
10 embryo MP:0005380 10.11 AR AUTS2 DSP EDNRA FOXN1 GJA1
11 hearing/vestibular/ear MP:0005377 10 AHSG EDNRA FOXN1 GJA1 HR KRT14
12 muscle MP:0005369 9.92 AHSG AR DSP EDNRA FOXN1 GJA1
13 neoplasm MP:0002006 9.86 AIRE ANTXR1 AR AUTS2 FOXN1 HR
14 reproductive system MP:0005389 9.85 AIRE ANTXR1 AR DCAF17 FOXN1 GJA1
15 skeleton MP:0005390 9.56 AHSG ANTXR1 AR EDNRA FOXN1 GJA1
16 vision/eye MP:0005391 9.17 AIRE EDNRA FOXN1 GJA1 HR KRT14

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 410)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
2 fluindione Approved, Investigational Phase 4 957-56-2
3
Rivaroxaban Approved Phase 4 366789-02-8
4
Phylloquinone Approved, Investigational Phase 4 84-80-0
5
Warfarin Approved Phase 4 81-81-2 6691 54678486
6
Dalteparin Approved Phase 4 9005-49-6
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
9
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
10
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13 Orange Approved Phase 4
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Drospirenone Approved Phase 4 67392-87-4 68873
19
Tofacitinib Approved, Investigational Phase 4 477600-75-2
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
22
Gemcitabine Approved Phase 4 95058-81-4 60750
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
25
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
26
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
27
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
28
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
29
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
31
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
32 Menaquinone Investigational Phase 4 1182-68-9
33
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
34 Emollients Phase 4
35 Keratolytic Agents Phase 4
36 Anticoagulants Phase 4
37 Serine Proteinase Inhibitors Phase 4
38 Antithrombin III Phase 4
39 Coagulants Phase 4
40 Antithrombins Phase 4
41 Antifibrinolytic Agents Phase 4
42 naphthoquinone Phase 4
43 Hemostatics Phase 4
44 Heparin, Low-Molecular-Weight Phase 4
45 Vitamin K Phase 4
46 Factor Xa Inhibitors Phase 4
47 Antivitamins K Phase 4
48 Interferon Inducers Phase 4
49 Neuroprotective Agents Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 426)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
5 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
6 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
7 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
8 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
9 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
10 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
12 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
13 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
14 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
15 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
16 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
17 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
18 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
19 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Recruiting NCT03800979 Phase 4 Tofacitinib
20 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
21 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
22 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
23 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
24 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
25 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
26 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Not yet recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
27 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
28 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
29 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
30 CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Unknown status NCT00054184 Phase 3 docetaxel;paclitaxel poliglumex
31 TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
32 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
33 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
34 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
35 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
36 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
37 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
38 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
39 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
40 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
41 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
42 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
43 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
44 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
45 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
46 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
47 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
48 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
49 Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer Completed NCT00952029 Phase 2, Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
50 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 29

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

41
Breast, Skin, Lung, T Cells, Ovary, Thyroid, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 16003)
# Title Authors PMID Year
1
A systematic simulation-based meta-analytical framework for prediction of physiological biomarkers in alopecia. 38
30993080 2019
2
JAK-inhibitors in dermatology: current evidence and future applications. 38
30433838 2019
3
Evaluation of a Handheld Dermatoscope in Clinical Diagnosis of Primary Cicatricial Alopecias. 38
31190216 2019
4
[Alopecia, deformed ear and mental retardation associated with terminal 21q deletion]. 38
30922549 2019
5
Identification of blood microRNA alterations in patients with severe active alopecia areata. 38
30983035 2019
6
Cyproterone acetate-loaded nanostructured lipid carriers: effect of particle size on skin penetration and follicular targeting. 38
30889371 2019
7
Platelet-rich plasma and its utility in medical dermatology: A systematic review. 38
31009668 2019
8
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. 38
30692587 2019
9
Patients with alopecia areata show signs of insulin resistance. 38
31089876 2019
10
Retrospective outcome analysis of 25 alopecia areata patients treated with simvastatin/ezetimibe. 38
31015012 2019
11
Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata. 38
30513014 2019
12
Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. 38
31048013 2019
13
Frontal fibrosing alopecia developing on vitiligo. 38
31322136 2019
14
Regulatory T-cells in alopecia areata. 38
30989699 2019
15
GAPO syndrome with craniosynostosis and intracranial hypertension. 38
31230109 2019
16
A clinical and immunological study of phototoxic regimen of ultraviolet A for treatment of alopecia areata: a randomized controlled clinical trial. 38
30411986 2019
17
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. 38
29355049 2019
18
Anterolateral leg alopecia: unknown entity or yet underreported? 38
30264393 2019
19
Ten clinical clues for the diagnosis of frontal fibrosing alopecia. 38
30073989 2019
20
Familial frontal fibrosing alopecia in two male families. 38
31166008 2019
21
Renaming frontal fibrosing alopecia is a step too far. 38
31085262 2019
22
Hair transplant in frontal fibrosing alopecia: A multicenter review of 51 patients. 38
31350039 2019
23
Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib. 38
31241173 2019
24
Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. 38
30411987 2019
25
A cross-sectional study of the histopathology and immunology of alopecia areata: Unearthing the role of the Janus kinase-signal transducer and activator of transcription pathway. 38
31031313 2019
26
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. 38
30843235 2019
27
Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test. 38
31165365 2019
28
An unusual case of Cheyletiellosis in a Persian cat and its therapeutic management. 38
31406422 2019
29
A Review of Topical Corticosteroid Foams 38
31424707 2019
30
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? 38
31145194 2019
31
Trichoscopy of whorled alopecia revealing "pigment incontinence" of incontinentia pigmenti. 38
31074001 2019
32
Successful use of topical minoxidil in the treatment of hypotrichosis associated with desmoplakin mutations. 38
31414503 2019
33
A previously undescribed cutaneous paraneoplastic syndrome in a cat with thymoma. 38
30908751 2019
34
The association among thyroid dysfunction, thyroid autoimmunity, and clinical features of alopecia areata: A retrospective study. 38
29753058 2019
35
Exacerbation of pathogenic Th17-cell-mediated cutaneous graft-versus-host-disease in human IL-1β and IL-23 transgenic humanized mice. 38
31230747 2019
36
Pharmacological Activation of Thermo-Transient Receptor Potential Vanilloid 3 Channels Inhibits Hair Growth by Inducing Cell Death of Hair Follicle Outer Root Sheath. 38
31152005 2019
37
Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the C3H/HeJ mouse. 38
31431342 2019
38
Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of  alopecia  areata? 38
31374131 2019
39
Phospholipid-polymer hybrid nanoparticles mediated transfollicular delivery of Quercetin: prospective implement for the treatment of androgenic alopecia. 38
31382790 2019
40
Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. 38
30706177 2019
41
Expression of anti-aging type-XVII collagen (COL17A1/BP180) in hair follicle-associated pluripotent (HAP) stem cells during differentiation. 38
31383286 2019
42
Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. 38
31272082 2019
43
Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use? 38
30912141 2019
44
Dermoscopic features of lichen planopilaris in Northern Iran: a prospective observational study. 38
31372982 2019
45
Scalp Avulsion Injuries and Replantation: Is Deep Temporal Artery an Alternate Option? 38
31397683 2019
46
Viremia and viruria of trichodysplasia spinulosa-associated polyomavirus before the development of clinical disease in a kidney transplant recipient. 38
31233669 2019
47
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. 38
30397836 2019
48
Method for describing patterns and distributions of alopecia areata which may be helpful for patient characterization and predicting prognosis. 38
31215678 2019
49
The Association between Genetic Variation in Wnt Transcription Factor TCF7L2 (TCF4) and Alopecia Areata. 38
31012334 2019
50
The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review. 38
31381252 2019

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SASH1 NM_015278.5(SASH1): c.1849G> A (p.Glu617Lys) single nucleotide variant Pathogenic/Likely pathogenic rs587781245 6:148855021-148855021 6:148533885-148533885
2 EMILIN2 ; LPIN2 ; METTL4 ; MYL12A ; MYL12B ; MYOM1 ; NDC80 ; SMCHD1 ; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance 18:1345040-3479168 :0-0

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

Pathways related to Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 GJA1 DSP CLDN1
2 10.3 GJA1 DSP CLDN1

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.62 GJA1 DSP

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 VDR TP63 FOXN1 AUTS2 AR AIRE
2 cell proliferation GO:0008283 9.8 TP63 FOXN1 EDNRA AR
3 skeletal system development GO:0001501 9.69 VDR TP63 AHSG
4 animal organ morphogenesis GO:0009887 9.5 VDR TP63 FOXN1
5 cell-cell junction organization GO:0045216 9.46 GJA1 CLDN1
6 decidualization GO:0046697 9.43 VDR GJA1
7 regulation of bone mineralization GO:0030500 9.4 GJA1 AHSG
8 establishment of skin barrier GO:0061436 9.37 TP63 CLDN1
9 keratinocyte differentiation GO:0030216 9.33 TP63 FOXN1 DSP
10 prostate gland development GO:0030850 9.26 TP63 AR
11 epidermis development GO:0008544 9.26 TP63 KRT14 FOXN1 DSP
12 thymus epithelium morphogenesis GO:0097536 8.62 FOXN1 AIRE

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....